Skip to main content

Requesting your support

Donate to cancer clinical trial research in Canada

Most cancer treatments used today were first proven effective through high-quality cancer clinical trials like those led by the Canadian Cancer Trials Group (CCTG). CCTG is a collaborative network of dedicated researchers, physicians, scientists and statisticians globally recognized for finding treatments that give people with cancer longer, better quality lives. Created in 1980, CCTG is the largest cancer research network in Canada with over 5200 active members and 2100 Canadian investigators. The group has also created an important international network with trials in over 40 countries. CCTG-led trials have resulted in major, life-saving breakthroughs in breast, colorectal, blood, lung, ovarian, brain and prostate cancer.

CCTG is a national program of the Canadian Cancer Society and your donation to clinical trial research supports the work that is done through the group across Canada.

CCTG is the most significant cancer research investment in Canada in terms of direct impact on patients.

However, despite this record of excellence and the countless number of lives saved, CCTG does not have stable funding and has to rely on grants, that are never assured, to continue their work. This means that many necessary trials are on hold or are taking longer to complete.

For example, the Challenge Trial, an international trial expected to improve colon cancer survival rates, is showing great promise but requires funding to test the impact of an exercise treatment on colon cancer survivors. The lack of stable support has slowed trial progress meaning that a potential new treatment has been delayed.

As our understanding of cancer grows, we rely on CCTG to safely conduct clinical trials based on new discoveries. While other organizations support CCTG, it is not enough for the number of trials that are needed. The cure for cancer will come from clinical trials. Your gift will enable CCTG researchers to safely conduct the growing number of trials needed to improve the lives of cancer patients across Canada and the world.

To support any of CCTG's high impact initiatives visit the CCTG Queen's donation page to donate online

Your support is what makes the difference!

Marathon of Hope Cancer Centres Network and Canadian Cancer Trials Group partner on three pan-Canadian projects aimed at making immunotherapy more effective for cancer patients

Marathon of Hope Cancer Centres Network and Canadian Cancer Trials Group partner on three pan-Canadian projects aimed at making immunotherapy more effective for cancer patients

A new partnership between the Marathon of Hope Cancer Centres Network (MOHCCN) and the Canadian Clinical Trials Group (CCTG) will support three pan-Canadian research teams aiming to better understand how immunotherapies can best be used to increase survival, reduce toxicities and improve quality of life for cancer patients in Canada.

More >>
 
CIHR has announced $3,056,176 in funding over 5 years, for the TACtful trial

CIHR has announces funding for the TACtful cell therapy trial

CIHR has announced $3,056,176 in funding over 5 years, for the TACtful trial investigating a novel cell therapy using the immune system to treat people with relapsed and refractory multiple myeloma.

More >>
 
 CCTG NE2 trial has been awarded $260,101 in the Spring CIHR grants announcement

CCTG NE2 trial successfully funded by CIHR

​The CCTG NE2 trial has been awarded $260,101 in the Spring CIHR grants announcement to support Canadian participation in the STOPNET clinical trial international trial, a Randomized Study of Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Mid-Gut Neuroendocrine Tumours.

More >>
 
CIHR funding announced for CCTG PR25

CIHR funding announced for CCTG PR25

The CIHR has announced funding, $1,828,350 over 6 years, for the CCTG PR25 trial, a metastatic prostate cancer personalized medicine study investigating the addition platinum-based chemotherapy to standard of care chemotherapy to evaluate markers believed to predict benefit.

More >>